RIG
RPRX icon

Roosevelt Investment Group’s Royalty Pharma RPRX Stock Holding History

Roosevelt Investment Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,336
Closed -$252K – 310
2021
Q4 		$252K Buy
+6,336
New +$246K 0.01% 247

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Roosevelt Investment Group's RPRX Position: Q1 2022 in Review

Roosevelt Investment Group sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 6,336 shares — an estimated $252K sold.

Roosevelt Investment Group first reported a position in RPRX in Q4 2021 and held it in 1 quarter. The position peaked at $252K in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

  • Roosevelt Investment Group reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
  • Roosevelt Investment Group sold 6,336 Royalty Pharma shares in Q1 2022, an estimated $252K.
  • Roosevelt Investment Group first reported a position in Royalty Pharma in Q4 2021 and held it in 1 quarter.
  • Roosevelt Investment Group's Royalty Pharma position peaked at $252K in Q4 2021.
  • 279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Roosevelt Investment Group's 13F filing for Q1 2022, filed 2 May 2022.